我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
16
5 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
2
12.5%
已完成
3
18.8%
尚未招募
招募中
暂停
1
6.3%
终止
5
31.3%
暂无批准数据
- BioRay Pharmaceutical's innovative BR111, the world's first anti-ROR1 Bi-paratopic ADC, has received clinical trial approval from China's NMPA for treating ROR1-positive cancers. - The drug combines dual-epitope targeting of ROR1 with CysX™ conjugation technology, demonstrating superior tumor-killing efficacy and improved safety in preclinical studies. - BR111 shows promise in treating multiple cancer types including lymphoma, breast, ovarian, and lung cancers, with potential for combination therapy applications.
